Henry Kaplan from University of Louisville School of Medicine: Combatting Retinal Degeneration with Glucose

Video

According to Henry Kaplan, MD, University of Louisville School of Medicine, "One has to recognize that there are multiple approaches like gene therapy, neuroprotection, stem cell transplantation, and pharmacologic manipulation of other genes really holds the greatest benefit in terms of trying to reverse the inevitable loss of vision."

At the ARVO 2016 meeting in Seattle, WA, Henry Kaplan, MD, University of Louisville School of Medicine, discussed how access to glucose that would normally be transplanted to the subretinal space for metabolism could aid in restoring normal rod function in retinal degeneration.

"One has to recognize that there are multiple approaches like gene therapy, neuroprotection, stem cell transplantation, and pharmacologic manipulation of other genes really holds the greatest benefit in terms of trying to reverse the inevitable loss of vision," Kaplan commented.

Related Videos
Shankar Ramaswamy, MD, the cofounder, chairman, and CEO of Kriya Therapeutics
Kevin Campbell, PhD, a Howard Hughes Investigator at the University of Iowa
Debora Mazzetti, MS, on Multitargeting MicroRNA in Glioblastoma
Abhishek Gupta, BS, the senior vice president of genetic medicines at Syneos Health
Francesca Del Bufalo, MD, PhD, a medical doctor and scientist at Bambino Gesù Chidren’s Hospital
Luke Roberts, MBBS, PhD, on Early Clinical Data on Congestive Heart Failure Gene Therapy
Lawrence R. Lustig, MD, the chair of the Department of Otolaryngology—Head and Neck Surgery at Columbia University College of Physicians
Casey Maguire, PhD, on Combining Viral-Like Particles and AAV
Travis Drow, BS, a research scientist at Seattle Children's Research Institute
Holly Peay, PhD, senior research scientist at RTI International
© 2024 MJH Life Sciences

All rights reserved.